Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of SecuritiesPMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced today the pricing of an underwritten public offering consisting of (i) 22,055,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 19,900,000 shares of its common stock, and (ii) accompanying warrants to purchase an aggregate of 41,955,000 shares of common stock. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock for each share of common stock or pre-funded warrant sold. The accompanying warrants have an initial exercise price of $1.21 per share, subject to adjustment following a specified regulatory milestone, are immediately exercisable from the date of issuance and will expire five years from the date of issuance.
- Radin LLCVALOR Network Selects RADIN™ Health to Power Federal Teleradiology Services, with Total Medical Imaging Providing Nationwide Physician CoverageVALOR Network expands its federal healthcare imaging capabilities through RADIN's secure cloud-based radiology platform and Total Medical Imaging's national network of radiologists supporting diagnostic imaging services for the Department of Veterans Affairs and Department of War....
- Health-ISAC® Invests in APAC with Key Staff Addition in AustraliaHealth-ISAC names Simon Cowley as APAC Health Sector Security & Partnerships Manager, based in Melbourne, to boost regional cyber resilience.
- Rutland Regional Medical Center RutlandRutland Regional Medical Center Earns Four U.S. News & World Report High Performing RatingsVermont hospital recognized for diabetes, hip replacement, knee replacement and hip fracture care in U.S. News’ 2026-2027 Best Hospitals procedure and condition ratings
- Ultra VioletteUltra Violette Becomes First Brand in the US to Launch a Sunscreen Containing Newly FDA-Approved Filter BemotrizinolCult Australian suncare brand debuts Unblock Screen™ SPF 50, the first US sunscreen formulated with Bemotrizinol (BEMT), approved by the FDA in June 2026 — Ultra Violette, the cult Australian suncare brand known for pairing high-performance SPF with...
- Enliven Therapeutics, Inc.Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual MeetingEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that the Company will present data from...
- Astellas Pharma Inc.Astellas enters voluntary agreement with U.S. government supporting affordable access to medicines– Agreement supports commitment to patient access, affordability and innovation – — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has reached an agreement with the U.S. government that reflects our...
- Disc Medicine IncDisc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual MeetingDisc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple clinical programs, including an oral presentation of initial data from the RESTORE-PV trial of DISC-3405 in patients with polycythemia vera (PV), at the SOHO Annual Meeting, which will be held in Houston, Texas on September 9-12, 2026.
- AN2 Therapeutics, Inc.AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual MeetingMENLO PARK, Calif., August 31, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidate for the treatment of polycythemia vera (PV), will be presented at the Society of Hematologic Onco
- Adicet Bio, Inc.Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)REDWOOD CITY, Calif., August 31, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced it granted an inducement award on August 31, 2026.
- SealaskaInvesting in the Future by Upholding Traditional ValuesSealaska, the Alaska Native regional corporation for Southeast Alaska, is building a future rooted in Indigenous values. By growing businesses that improve ocean health around the world, Sealaska generates sustainable revenue that is reinvested in shareholders, communities, culture and...
- Greenway Greenhouse Cannabis CorporationGreenway Reports First Quarter Fiscal 2027 Financial ResultsGreenway Greenhouse Cannabis Corporation (CSE: GWAY) (OTCQB: GWAYF) ("Greenway" or the "Company"), a cultivator of high-quality greenhouse cannabis for the Canadian and international medical cannabis markets, today announced its unaudited...